Answers are grounded in this paper and cite their sources.
Within 5 months of study activation, we obtained pivotal biochemical and pharmacokinetic data that have guided the design of subsequent phase I trials of ABT-888 in combination with DNA-damaging agents. In addition to accelerating the development of ABT-888, the rapid conclusion of this trial demonstrates the feasibility of conducting proof-of-principle phase 0 trials as part of an alternative paradigm for early drug development in oncology.
No takes yet. Share an insight, caveat, or question.
Kummar et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: